We are pleased to read that Germer et al. confirm our results 1 showing that the Cobas AmpliPrep/Cobas TaqMan assay (CAP/CTM; Roche Molecular Systems, Pleasanton, CA) underestimates hepatitis C virus (HCV) RNA levels in a substantial number of patients infected with HCV genotype 4. We recently repor
Quantification of genotype 4 hepatitis C virus RNA by the COBAS AmpliPrep/COBAS TaqMan hepatitis C virus test
β Scribed by Jeffrey J. Germer; Carl E. Bommersbach; Dana M. Schmidt; Jordan L. Bendel; Joseph D. C. Yao
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 146 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
LT). Six patients (30%) with LF were not treated medically, of whom five had submassive necrosis on liver biopsy. Five of these six patients underwent transplantation and all but one survived. One could not undergo transplantation due to development of fatal cholangitis. In conclusion, about 20% of
Quantitation of low hepatitis B virus (HBV) DNA levels in patients with chronic hepatitis B is important for monitoring natural history of disease and treatment efficacy. This study aimed to compare the quantitation range and analytical sensitivity of the newly developed COBAS TaqMan HBV test (TaqMa
The quantitation of serum levels of hepatitis C virus RNA in chronic hepatitis C has been regarded as one of the most important indicators for the outcome of interferon therapy. A new method was used for quantitating the copy number of hepatitis C virus RNA using TaqMan polymerase chain reaction and
## Abstract The storage conditions of blood samples for reliable results are very important in hepatitis C virus (HCV) RNA amplification tests used in routine HCV analyses. According to many studies, storage conditions could affect the RNA stability for HCV RNA detection. We have studied HCV RNA st